ebook_ADHD2019_engl.

36 Rohde, Buitelaar, Gerlach & Faraone 16. Vanicek T, Spies M, Rami-Mark C, Savli M, Höflich A, Kranz GS, et al. The norepinephrine transporter in attention-deficit/hyperactivity disorder investigated with positron emission tomography. JAMA Psychia- try. 2014;71(12):1340-1349. 17. Klein M, Onnink M, van Donkelaar M, Wolfers T, Harich B, Shi Y, et al. Brain imaging genetics in ADHD and beyond – mapping pathways from gene to disorder at different levels of complexity. Neurosci Biobehav Rev. 2017;80:115-155. 18. Banerjee E, Nandagopal K. Does serotonin deficit mediate susceptibility to ADHD? Neurochem Int. 2015;82:52-68. 19. Gizer IR, Ficks C, Waldman ID. Candidate gene studies of ADHD: a meta-analytic review. Hum Genet. 2009;126(1):51-90. 20. van der Meer D, Hartman CA, Richards J, Bralten JB, Franke B, Oosterlaan J, et al. The serotonin transporter gene polymorphism 5-HTTLPR moderates the effects of stress on attention-deficit/hyperactivity disorder. J Child Psychol Psychiatry. 2014;55(12):1363-71. 21. Zhou Y, Danbolt NC. Glutamate as a neurotransmitter in the healthy brain. J Neural Transm (Vienna). 2014;121(8):799-817. 22. Gregory KJ, Noetzel MJ, Niswender CM. Pharmacology of metabotropic glutamate receptor allos- teric modulators: structural basis and therapeutic potential for CNS disorders. Prog Mol Biol Transl Sci. 2013;115:61-121. 23. Elia J, Glessner JT, Wang K, Takahashi N, Shtir CJ, Hadley D, et al. Genome-wide copy number variation study associates metabotropic glutamate receptor gene networks with attention deficit hyperactivity disor- der. Nat Genet. 2011;44(1):78-84. 24. Naaijen J, Bralten J, Poelmans G, IMAGE consortium, Glennon JC, Franke B, et al. Glutamatergic and GABAergic gene sets in attention-deficit/hyperactivity disorder: association to overlapping traits in ADHD and autism. Transl Psychiatry. 2017;7(1):e999. 25. Naaijen J, Lythgoe DJ, Amiri H, Buitelaar JK, Glennon JC. Fronto-striatal glutamatergic compounds in compulsive and impulsive syndromes: a review of magnetic resonance spectroscopy studies. Neurosci Biobehav Rev. 2015;52:74-88. 26. Brown RE, Stevens DR, Haas HL. The physiology of brain histamine. Prog Neurobiol. 2001;63(6):637- 72. 27. Miyazaki C, Koyama M, Ota E, Swa T, Mlunde LB, Amiya RM, et al. Allergic diseases in children with at- tention deficit hyperactivity disorder: a systematic review and meta-analysis. BMC Psychiatry. 2017;17(1):120. 28. Sadek B, Saad A, Sadeq A, Jalal F, Stark H. Histamine H3 receptor as a potential target for cognitive symptoms in neuropsychiatric diseases. Behav Brain Res. 2016;312:415-30. 29. Moorthy G, Sallee F, Gabbita P, Zemlan F, Sallans L, Desai PB. Safety, tolerability and pharmacokinetics of 2-pyridylacetic acid, a major metabolite of betahistine, in a phase 1 dose escalation study in subjects with ADHD. Biopharm Drug Dispos. 2015;36(7):429-39. 30. Potter AS, Newhouse PA, Bucci DJ. Central nicotinic cholinergic systems: a role in the cognitive dysfunc- tion in attention-deficit/hyperactivity disorder? Behav Brain Res. 2006;175(2):201-11. 31. Williams NM, Franke B, Mick E, Anney RJ, Freitag CM, Gill M, et al. Genome-wide analysis of copy number variants in attention deficit hyperactivity disorder: the role of rare variants and duplications at 15q13.3. Am J Psychiatry. 2012;169(2):195-204. 32. Potter AS, Schaubhut G, Shipman M. Targeting the nicotinic cholinergic system to treat attention-deficit/ hyperactivity disorder: rationale and progress to date. CNS Drugs. 2014;28(12):1103-13.